Chikungunya – VLA1553

Book a meeting

Valneva’s single-shot chikungunya vaccine – IXCHIQ®/ VLA1553

  • IXCHIQ® was the world’s first licensed chikungunya vaccine available to addresses this significant unmet medical need.
  • It is approved in Europe[2] for the prevention of disease caused by the Chikungunya virus in individuals 12 years of age and older. In the US[1], Canada[3], the United Kingdom[4] and Brazil, it is approved in individuals 18 and older.
  • Label extension applications are under review in the U.S., UK and Canada to potentially extend the use of IXCHIQ® to adolescents 12 to 17 years of age.
  • To make  IXCHIQ® more accessible to Low- and Middle-Income Countries (LMIC),  Valneva entered a partnership with the Coalition for Epidemic Preparedness (CEPI) in 2019, with support from the European Union (EU) Horizon program, and received a $24.6 million grant. This partnership was extended in 2024[6] through a new $41.3 million grant.
  • Within the framework of its CEPI agreement, Valneva announced an exclusive license agreement with the Serum Institute of India (SII)[7] to enable supply of its chikungunya vaccine in Asia. This new agreement complements the license agreement Valneva signed in 2021 with Instituto Butantan in Brazil enabling supply of its chikungunya vaccine in Latin American countries.
  • Additionally, Valneva is continuing to generate additional clinical data to support label extensions and further establish IXCHIQ® as a differentiated brand. The Company notably reported positive three-year Phase 3 persistence data demonstrating antibody persistence in 96% of study participants, positive twelve-month Phase 3 data in adolescents and the world’s first positive Phase 2 pediatric data for a chikungunya vaccine.

 

Valneva’s press releases about VLA1553

[1] Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ® – Valneva

[2] Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ® – Valneva

[3] Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ® – Valneva

[4] Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ® – Valneva

[5] Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ® – Valneva

[6] CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine – Valneva

[7] Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India – Valneva